ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints

MT Newswires Live

04-25

ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.

The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.

ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.

ALX Oncology shares were down more than 4% in recent Friday trading.

Price: 0.58, Change: -0.02, Percent Change: -3.49

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2530131735"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2530131735\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2530131735?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-25 21:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2530131735","market":"fut","top_or_hot":-1,"title":"ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints","media":"MT Newswires Live","content":"<html><body><p> ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.</p><p>The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.</p><p>ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.</p><p>ALX Oncology shares were down more than 4% in recent Friday trading.</p><p>Price: 0.58, Change: -0.02, Percent Change: -3.49</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-04-25 21:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.</p><p>The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.</p><p>ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.</p><p>ALX Oncology shares were down more than 4% in recent Friday trading.</p><p>Price: 0.58, Change: -0.02, Percent Change: -3.49</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2530131735","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2530131735","pubTimestamp":1745589120,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ALX Oncology  said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's  Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.ALX Oncology shares were down more than 4% in recent Friday trading.Price: 0.58, Change: -0.02, Percent Change: -3.49","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"ALX Oncology的Evorpacept、Keytruda组合治疗头颈癌的2期试验未能达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALX":1,"ALXO":0.9,"MRK":1},"content_text":"ALX Oncology (ALXO) said Friday that two phase 2 trials evaluating evorpacept in combination with Merck's (MRK) Keytruda in patients with advanced head and neck squamous cell carcinoma failed to meet their primary endpoints of improved objective response rates.The company said efficacy data from the trials do not support advancing the combination into a registrational study and it will no longer pursue the combination therapy in advanced head and neck squamous cell carcinoma.ALX said, however, that several trials of evorpacept in combination with other anti-cancer antibodies will continue based on established proof-of-concept.ALX Oncology shares were down more than 4% in recent Friday trading.Price: 0.58, Change: -0.02, Percent Change: -3.49","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}